drugset / Trial / NCT00613106

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)

NCT00613106

Phase 3 Completed 179 enrolled Amgen
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.

Timeline

Start
2007-09
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Famotidine Other / unclassified 26.6 mg Oral
Comparator Ibuprofen Small molecule 800 mg Oral